Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M 

A VC syndicate that backed IFM and serial dealmaker Gary Glick has launched precision oncology start-up Scorpion, where Glick will be president and CEO, with $108 million in series A funding.

Scorpion Therapeutics Inc. intends to be a next-generation targeted medicines developer that will create best-in-class therapies around validated targets, develop new drugs against difficult-to-reach targets, and explore new targets in oncology...